BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) is a global biotechnology company that develops and commercializes medicines for hereditary angioedema (HAE) and other rare diseases. Its commercial product ORLADEYO (berotralstat), an oral, once-daily therapy to prevent HAE attacks, is approved in the United States and… From the company’s description.
Over the twelve months to Sep 30, 2026, BioCryst Pharmaceuticals, Inc. reported revenue of $961.51M, up 60.3% from a year earlier, and a net loss of $359.66M. Its operating margin was −30.1%, and operations generated $367.49M in cash. In fiscal 2025, it reported revenue of $874.84M, up 94.1% from fiscal 2024, and net income of $263.86M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What BioCryst Pharmaceuticals, Inc. does
In the company’s own words
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) is a global biotechnology company that develops and commercializes medicines for hereditary angioedema (HAE) and other rare diseases. Its commercial product ORLADEYO (berotralstat), an oral, once-daily therapy to prevent HAE attacks, is approved in the United States and multiple global markets; its oral pellet formulation is approved in the United States for children aged 2 to under 12. The company also markets peramivir injection under the RAPIVAB, RAPIACTA and PERAMIFLU brands, with commercialization in several territories handled by partners. Its development pipeline includes navenibart for HAE, BCX17725 for Netherton syndrome, avoralstat for diabetic macular edema and STAR-0310 for atopic dermatitis. BioCryst combines internal drug discovery and development with external licensing and business development, and uses its commercial infrastructure alongside regional partners to support product sales. In January 2026, it acquired Astria Therapeutics, adding navenibart and STAR-0310 to its portfolio.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- DURHAM, NC
- Fiscal year end
- December
- CIK
- 882796
- SIC
- 2836
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns BioCryst Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · BioCryst Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do BioCryst Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of BioCryst Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in BioCryst Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”